CD8A and neoplasm: Improving antitumor responses and animal survival compared with monotherapy with anti‐PD‐L1 or VSV‐mIFNβ‐NIS Reducing tumor burden in various organs of the studied mice Increasing the frequency of effector CD4+ and CD8+ TILs in the TME